m.LearnBecome a PartnerBecome a Partner
m.Stock by Mirae AssetOpen Demat Account
m.Stock by Mirae Asset
LoginOpen Demat Account
m.Stock by Mirae Asset
LoginOpen Demat Account
Glenmark Pharmaceuticals Ltd logo

Glenmark Pharmaceuticals Ltd Share Price

Current price unavailable.
As on - | -
PharmaceuticalsMid Cap
BuySell

Volume Analysis

Futures

    SPOT Pivot Levels

    TypeClassicFibonacci
    R1 2,356.832,356.37
    R22,387.772,368.36
    R32,407.632,387.77
    PP2,336.97 2,336.97
    S12,356.832,356.37
    S22,286.172,305.57
    S3 2,255.232,286.17

    Ratios

    ParticularsDec 2025Sep 2025Jun 2025Mar 2025Dec 2024
    ROCE-6.96-8.65-
    ROE-6.15-6.57-
    EPS10-26.1911.75.2414.66

    Peer Comparison

    No data available
    Scrip NamePriceDaily changeM CapPE Ratio1 Year Return

    Corporate Action

    April 30, 2026
    Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

    Sr. No. Particulars Details
    1Name of CompanyGlenmark Pharmaceuticals Ltd
    2CIN NO.L24299MH1977PLC019982
    3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
    4Highest Credit Rating during the previous FY AA
    4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD.
    5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkNSE


    We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



    Name of the Company Secretary: Harish Kuber
    Designation: Company Secretary and Compliance Officer
    EmailId: Harish.Kuber@glenmarkpharma.com
    Name of the Chief Financial Officer: Anurag Mantri
    Designation: Executive Director and Global Chief Financial Officer
    EmailId: Anurag.Mantri@glenmarkpharma.com

    Date: 30/04/2026

    Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
    April 30, 2026
    Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

    Sr. No. Particulars Details
    1 Name of Company Glenmark Pharmaceuticals Ltd
    2 CIN NO. L24299MH1977PLC019982
    3 Report filed for FY 2025-2026
    Details of the Current block (all figures in Rs crore):
    4 2 - year block period (Specify financial years)* 2024-2025 2025-2026
    5 Incremental borrowing done in FY (T)(a) 0.00
    6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
    7 Actual borrowing done through debt securities in FY (T)(c) 0.00
    8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
    8Quantum of (d) which has been met from (c)(e)* 0
    9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


    Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
    2 - year Block period (Specify financial years)2024-2025 2025-2026
    Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



    Name of the Company Secretary :-Harish Kuber
    Designation :-Company Secretary and Compliance Officer
    Name of the Chief Financial Officer :- Anurag Mantri
    Designation : -Executive Director and Global Chief Financial Officer

    Date: 30/04/2026

    About Glenmark Pharmaceuticals Ltd

    Equity img
    Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets....
    ISIN :INE935A01035

    Registered Office

    B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road

    Contact number

    + 91-22-40189999

    Email

    Registrars

    KFin Techologies Ltd
    Karvy Selenium Tow-B 31&32 Financial Dist Nanakramguda Hyderabad-500032

    Contact number

    + 91-40-67162222

    Email

    Management

    Glenn Saldanha (Chairman)

    Glenn Saldanha (Director)

    Open IPO’s

    View All

    FAQs

    The share price of Glenmark Pharmaceuticals Ltd on the BSE is - as on -

    Note : Securities shown above are only for illustrative purposes and not recommendatory in nature. The data represents best/cumulative figures till date.